Highlights

  • Argent BioPharma (ASX:RGT) expanded its commercial portfolio in September 2026 through an exclusive licence covering selected antiviral products.
  • The agreement covers Tollovir, Tollovid and NutraVir commercialisation rights across markets worldwide excluding China.
  • FY26 Revenue was A$161,187, while the company’s net loss narrowed to approximately A$7.7 million from A$17.8 million in FY25.
  • At the time of writing this article, Argent BioPharma (ASX:RGT) was trading at AUD 0.034, up 21.43% during today’s trading session.

At the time of writing this article, Argent BioPharma (ASX:RGT) was trading at AUD 0.034, up 21.43% during today’s trading session. Argent BioPharma is a clinical-stage biopharmaceutical company developing and commercialising treatments targeting neurological, inflammatory and immune-related conditions. Its portfolio includes CannEpil, CimetrA and other development programs. The company has recently broadened its commercial activities through an antiviral licensing agreement while continuing regulatory and commercial work across its existing healthcare pipeline.

Company Business

Argent BioPharma develops pharmaceutical therapies aimed at areas including drug-resistant epilepsy, systemic inflammation and other neurological or immune-mediated conditions. CannEpil is being developed around refractory epilepsy, while CimetrA forms part of the company’s immune-modulation and anti-inflammatory strategy. The Business also maintains other pharmaceutical development programs, including CogniCann.

The company operates across several international markets and has built patient and commercial exposure in Australia, the United Kingdom, Brazil and Ireland. During 2026, Argent also expanded the scope of CannEpil into veterinary healthcare and commenced a United States veterinary development program. In August, the company announced that the US Food and Drug Administration’s Center for Veterinary Medicine had established an Investigational New Animal Drug file for the CannEpil veterinary program.

Recent Development

In late September 2026, Argent entered an exclusive, royalty-bearing licence agreement covering selected antiviral applications associated with Tollovir, Tollovid and NutraVir. The commercialisation rights extend worldwide excluding China, subject to certain existing arrangements in the United States. The transaction adds antiviral products to Argent’s commercial portfolio alongside its existing immune-modulation activities.

Under the agreement, Argent is required to pay a monthly licence fee of US$15,000 for 20 months. Royalties are structured at 12% on the first US$2.5 million of cumulative net sales for each licensed product, 9% on the next US$2.5 million and 6% thereafter. Cash milestone payments of US$100,000 and US$125,000 are linked to aggregate cumulative net sales of US$2.5 million and US$5 million respectively. The arrangement also contemplates up to two million performance rights, subject to Shareholder approval.

Separately, Argent announced the execution of a Loan Facility agreement in early October 2026. The announcement followed several financing-related updates during the year, including funding received under an existing financing facility in July and August.

Financial Performance and Sector Context

For the year ended 30 June 2026, Argent reported revenue of A$161,187, compared with A$180,565 in FY25. The net loss narrowed to approximately A$7.7 million from A$17.84 million in the previous financial year. The result reflected a period in which the company continued restructuring its operations while allocating resources towards pharmaceutical development and commercialisation activities.

Cash management remains relevant for Argent because clinical-stage biotechnology companies typically incur development, regulatory and commercialisation expenditure before products generate material recurring revenue. During the June 2026 quarter, Argent reported approximately A$4.09 million of operating cash outflows for FY26. Financing arrangements therefore remain an important component of its financial position as development programs progress.

Across the healthcare sector, biotechnology companies remain exposed to regulatory timelines, clinical development requirements, Manufacturing costs and the ability to establish commercial distribution channels. Argent’s strategy increasingly combines internally developed programs with licensing arrangements intended to broaden its commercial portfolio.

Risks to Consider

Argent remains exposed to clinical development and regulatory risks, including the possibility that pharmaceutical or veterinary programs may require additional studies, approvals or expenditure before commercialisation. The company also faces funding requirements associated with research, regulatory work and operating activities.

The antiviral licence introduces additional commercial obligations, including monthly licence fees, royalties and milestone-linked payments. Revenue generation will depend on product demand, market access and the company’s ability to execute its commercialisation plans. Financing arrangements may also affect the company’s Capital Structure and future funding requirements.

What to Watch Next

Investors may monitor progress under the antiviral licence, including commercialisation activity for Tollovir, Tollovid and NutraVir and any shareholder approval process associated with performance rights.

CannEpil remains another area to monitor, particularly the US veterinary development program and future regulatory milestones following establishment of the INAD file. Further updates regarding CimetrA, financing arrangements, operating cash flows and subsequent financial reporting periods may also provide additional information about Argent’s development and commercial priorities.

Key Insights

Argent BioPharma entered the final quarter of 2026 with a broader healthcare portfolio spanning neurological, immune-modulation, veterinary and antiviral applications. The company’s latest developments include the NLC antiviral licence, continued CannEpil regulatory work and financing activity. FY26 results showed lower revenue but a reduced annual loss compared with FY25. Future attention is likely to remain on commercial execution, regulatory progress, cash requirements and the development of its pharmaceutical portfolio.